Primary Cutaneous Methotrexate-Associated T-Cell Lymphoproliferative Disorder in the Setting of Autoimmune Disease: A Case Series and Review of the Literature

Overview

Journal Am J Dermatopathol

Date 2025 Jan 24

PMID 39851907

Authors

Sarah Nocco

Cynthia Magro

Affiliations

Soon will be listed here.

Abstract

Methotrexate (MTX), an antimetabolite targeting certain autoimmune conditions and various hematologic malignancies, has been associated with iatrogenic lymphoproliferative disease (LPD) primarily of B-cell lineage. Less commonly are T-cell neoplasms where primary skin involvement is considered rare. Three cases were encountered in the medical practice of one of the authors. The patients ranged in age from 38 years to 99 years (2 women and 1 man) with 2 having rheumatoid arthritis and 1 having ankylosing spondylitis. All 3 patients received MTX. The cases included subcutaneous peripheral T-cell lymphoma not otherwise specified (NOS) (1 patient), mycosis fungoides (1 patient), and a primary aggressive epidermotropic cytotoxic T-cell lymphoma (1 patient) that proved to be fatal. One patient had spontaneous regression following MTX withdrawal; she later developed a recurrence while off MTX. Two patients died, 1 of unrelated causes and 1 of lymphoma. Seven previously reported cases included subcutaneous panniculitis-like T-cell lymphoma (2 cases), primary cutaneous CD4+ LPD (2 cases), peripheral T-cell lymphoma (NOS) (1 case), anaplastic large cell lymphoma (1 case), and peripheral T-cell lymphoma localized to fat (1 case). Regression without recurrence occurred in 6 of the 7 patients with MTX withdrawal. The patients were on the MTX for an average of 4 years and had a median age of 61 years with a slight dominance of men over women. Three of the 7 cases showed Epstein-Barr encoding region (EBER) positivity while the 3 cases reported in this series were negative. MTX-associated T-cell LPD involves older patients on long-term MTX where EBER positivity is more frequent than extracutaneous MTX-associated T-cell LPD. A spectrum of classic forms of CTCL is seen with subcutaneous involvement representing a significant percentage of cases. Regression with MTX withdrawal occurs although not in every case.

References

Cipriani P, Ruscitti P, Carubbi F, Liakouli V, Giacomelli R . Methotrexate: an old new drug in autoimmune disease. Expert Rev Clin Immunol. 2014; 10(11):1519-30. DOI: 10.1586/1744666X.2014.962996. View

Satou A, Nakamura S . EBV-positive B-cell lymphomas and lymphoproliferative disorders: Review from the perspective of immune escape and immunodeficiency. Cancer Med. 2021; 10(19):6777-6785. PMC: 8495296. DOI: 10.1002/cam4.4198. View

Omori I, Kawanabe R, Hashimoto Y, Mitsui A, Kodama K, Nogi S . Cutaneous methotrexate-related T-cell lymphoproliferative disorder with CD4, CD30, CD56, EBV-positive tumor cell infiltration: a case illustration and a brief review. Am J Blood Res. 2021; 11(2):163-167. PMC: 8165712. View

Satou A, Banno S, Kohno K, Takahara T, Takahashi E, Nobata H . Primary cutaneous methotrexate-associated B-cell lymphoproliferative disorders other than EBV-positive mucocutaneous ulcer: clinical, pathological, and immunophenotypic features. Pathology. 2021; 53(5):595-601. DOI: 10.1016/j.pathol.2020.10.019. View

Satou A, Tsuzuki T, Nakamura S . Other Iatrogenic Immunodeficiency-Associated Lymphoproliferative Disorders with a T- or NK-cell phenotype. J Clin Exp Hematop. 2019; 59(2):56-63. PMC: 6661958. DOI: 10.3960/jslrt.19013. View

Mukai H, Hasegawa Y, Kojima H, Okoshi Y, Takei N, Yamashita Y . Nodal CD8 positive cytotoxic T-cell lymphoma: a distinct clinicopathological entity. Mod Pathol. 2002; 15(11):1131-9. DOI: 10.1097/01.MP.0000036343.61268.64. View

Rizzi R, Curci P, Delia M, Rinaldi E, Chiefa A, Specchia G . Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature. Med Oncol. 2008; 26(1):1-9. DOI: 10.1007/s12032-008-9069-8. View

Berti E, Tomasini D, Vermeer M, Meijer C, Alessi E, Willemze R . Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999; 155(2):483-92. PMC: 1866866. DOI: 10.1016/S0002-9440(10)65144-9. View

Feng W, Cohen J, Fischer S, Li L, Sneller M, Goldbach-Mansky R . Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst. 2004; 96(22):1691-702. DOI: 10.1093/jnci/djh313. View

10.

Kohno K, Suzuki Y, Elsayed A, Sakakibara A, Takahara T, Satou A . Immunohistochemical Assessment of the Diagnostic Utility of PD-L1 (Clone SP142) for Methotrexate-Associated Lymphoproliferative Disorders With an Emphasis of Neoplastic PD-L1 (Clone SP142)-Positive Classic Hodgkin Lymphoma Type. Am J Clin Pathol. 2020; 153(5):571-582. DOI: 10.1093/ajcp/aqz198. View

11.

Bangert C, Costner M . Methotrexate in dermatology. Dermatol Ther. 2007; 20(4):216-28. DOI: 10.1111/j.1529-8019.2007.00135.x. View

12.

Kondo S, Tanimoto K, Yamada K, Yoshimoto G, Suematsu E, Fujisaki T . Mature T/NK-cell lymphoproliferative disease and Epstein-Barr virus infection are more frequent in patients with rheumatoid arthritis treated with methotrexate. Virchows Arch. 2013; 462(4):399-407. DOI: 10.1007/s00428-013-1389-1. View

13.

Natkunam Y, Gratzinger D, Chadburn A, Goodlad J, Chan J, Said J . Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?. Blood. 2018; 132(18):1871-1878. PMC: 6213318. DOI: 10.1182/blood-2018-04-842559. View

14.

Thomas E, Brewster D, Black R, Macfarlane G . Risk of malignancy among patients with rheumatic conditions. Int J Cancer. 2000; 88(3):497-502. View

15.

Satou A, Tabata T, Miyoshi H, Kohno K, Suzuki Y, Yamashita D . Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases. Mod Pathol. 2019; 32(8):1135-1146. DOI: 10.1038/s41379-019-0264-2. View

16.

Ellman M, Hurwitz H, Thomas C, Kozloff M . Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol. 1991; 18(11):1741-3. View

17.

Matsuoka A, Fujii K, Higashi Y, Yoshimitsu M, Arakawa F, Ohshima K . Subcutaneous panniculitis-like T-cell lymphoma associated with methotrexate treatment. J Dermatol. 2022; 49(12):e430-e432. DOI: 10.1111/1346-8138.16524. View

18.

Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T . Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology (Oxford). 2017; 56(6):940-946. DOI: 10.1093/rheumatology/kex002. View

19.

Swerdlow S, Jaffe E, Brousset P, Chan J, de Leval L, Gaulard P . Cytotoxic T-cell and NK-cell lymphomas: current questions and controversies. Am J Surg Pathol. 2014; 38(10):e60-71. PMC: 6329302. DOI: 10.1097/PAS.0000000000000295. View

20.

Shimizu S, Inokuma D, Murata J, Kikuchi K, Ito T, Fukasawa Y . Cutaneous manifestations of methotrexate-associated lymphoproliferative disorders: report of two cases and a review of the literature. Acta Derm Venereol. 2014; 95(3):366-7. DOI: 10.2340/00015555-1951. View